Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
Status:
Unknown status
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
To test the feasibility of studying effects of smoking cessation with varenicline on
antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of
smoking cessation treatment with varenicline in 10 schizophrenia or schizoaffective disorder
patients who are actively smoking and have pre-existing TD while receiving stable doses of
antipsychotics. Subjects will be followed after a 2 week baseline period to assess changes in
smoking status and neurological symptoms using standardized rating scales. The aim is to
examine clinically significant effects on antipsychotic-induced neurological side effects
that may warrant further investigation.